Clinical subsets of scleroderma

Relevance of fluorescent and precipitating antinuclear antibodies

F. Cassani, Antonella Tosti, F. B. Bianchi, M. Fusconi, L. Selleri, L. Baffoni, S. Veronesi, U. Volta, M. Lenzi, E. Pisi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Sera from 7 patients with localized and 35 with systemic scleroderma were studied for the presence of fluorescent antinuclear antibodies (FANA) (by indirect immunofluorescence on HEp-2 cells) and antibodies to extractable nuclear antigens (anti-ENA) (by immunodiffusion - ID - and counterimmunoelectrophoresis - CIE). In localized disease, antinuclear autoimmunity was limited to 1 FANA positive serum (14%); in systemic disease, the prevalence of FANA was 94% and that of anti-FANA ranged from 29% to 49% (by ID and CIE, respectively). The commonest ENA system, Scl-70, could be easily detected by CIE, in spite of the reported basic nature of the antigen. The anticentromere antibody occurred only in patients with acrosclerosis (7/26 - 27%), whereas the association of nucleolar + homogeneous FANA, as well as the anti-Scl-70, were found more frequently in diffuse scleroderma (9/9 - 100% and 6/9 - 67%, respectively). The presence of the anticentromere antibody excluded that of any anti-ENA, while a close association was found between nucleolar + homogeneous FANA and the anti-Scl-70. Pulmonary involvement was significantly more frequent in nucleolar + homogeneous FANA positive patients; moreover, in two cases the same pattern proved to predict the development of diffuse scleroderma.

Original languageEnglish
Pages (from-to)23-28
Number of pages6
JournalClinical and Experimental Rheumatology
Volume5
Issue number1
StatePublished - Sep 16 1987
Externally publishedYes

Fingerprint

Antinuclear Antibodies
Diffuse Scleroderma
Nuclear Antigens
Counterimmunoelectrophoresis
Antibodies
Systemic Scleroderma
Immunodiffusion
Indirect Fluorescent Antibody Technique
Serum
Autoimmunity
Antigens
Lung

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Cassani, F., Tosti, A., Bianchi, F. B., Fusconi, M., Selleri, L., Baffoni, L., ... Pisi, E. (1987). Clinical subsets of scleroderma: Relevance of fluorescent and precipitating antinuclear antibodies. Clinical and Experimental Rheumatology, 5(1), 23-28.

Clinical subsets of scleroderma : Relevance of fluorescent and precipitating antinuclear antibodies. / Cassani, F.; Tosti, Antonella; Bianchi, F. B.; Fusconi, M.; Selleri, L.; Baffoni, L.; Veronesi, S.; Volta, U.; Lenzi, M.; Pisi, E.

In: Clinical and Experimental Rheumatology, Vol. 5, No. 1, 16.09.1987, p. 23-28.

Research output: Contribution to journalArticle

Cassani, F, Tosti, A, Bianchi, FB, Fusconi, M, Selleri, L, Baffoni, L, Veronesi, S, Volta, U, Lenzi, M & Pisi, E 1987, 'Clinical subsets of scleroderma: Relevance of fluorescent and precipitating antinuclear antibodies', Clinical and Experimental Rheumatology, vol. 5, no. 1, pp. 23-28.
Cassani, F. ; Tosti, Antonella ; Bianchi, F. B. ; Fusconi, M. ; Selleri, L. ; Baffoni, L. ; Veronesi, S. ; Volta, U. ; Lenzi, M. ; Pisi, E. / Clinical subsets of scleroderma : Relevance of fluorescent and precipitating antinuclear antibodies. In: Clinical and Experimental Rheumatology. 1987 ; Vol. 5, No. 1. pp. 23-28.
@article{4e814650b38944319176e27f45a73a12,
title = "Clinical subsets of scleroderma: Relevance of fluorescent and precipitating antinuclear antibodies",
abstract = "Sera from 7 patients with localized and 35 with systemic scleroderma were studied for the presence of fluorescent antinuclear antibodies (FANA) (by indirect immunofluorescence on HEp-2 cells) and antibodies to extractable nuclear antigens (anti-ENA) (by immunodiffusion - ID - and counterimmunoelectrophoresis - CIE). In localized disease, antinuclear autoimmunity was limited to 1 FANA positive serum (14{\%}); in systemic disease, the prevalence of FANA was 94{\%} and that of anti-FANA ranged from 29{\%} to 49{\%} (by ID and CIE, respectively). The commonest ENA system, Scl-70, could be easily detected by CIE, in spite of the reported basic nature of the antigen. The anticentromere antibody occurred only in patients with acrosclerosis (7/26 - 27{\%}), whereas the association of nucleolar + homogeneous FANA, as well as the anti-Scl-70, were found more frequently in diffuse scleroderma (9/9 - 100{\%} and 6/9 - 67{\%}, respectively). The presence of the anticentromere antibody excluded that of any anti-ENA, while a close association was found between nucleolar + homogeneous FANA and the anti-Scl-70. Pulmonary involvement was significantly more frequent in nucleolar + homogeneous FANA positive patients; moreover, in two cases the same pattern proved to predict the development of diffuse scleroderma.",
author = "F. Cassani and Antonella Tosti and Bianchi, {F. B.} and M. Fusconi and L. Selleri and L. Baffoni and S. Veronesi and U. Volta and M. Lenzi and E. Pisi",
year = "1987",
month = "9",
day = "16",
language = "English",
volume = "5",
pages = "23--28",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "1",

}

TY - JOUR

T1 - Clinical subsets of scleroderma

T2 - Relevance of fluorescent and precipitating antinuclear antibodies

AU - Cassani, F.

AU - Tosti, Antonella

AU - Bianchi, F. B.

AU - Fusconi, M.

AU - Selleri, L.

AU - Baffoni, L.

AU - Veronesi, S.

AU - Volta, U.

AU - Lenzi, M.

AU - Pisi, E.

PY - 1987/9/16

Y1 - 1987/9/16

N2 - Sera from 7 patients with localized and 35 with systemic scleroderma were studied for the presence of fluorescent antinuclear antibodies (FANA) (by indirect immunofluorescence on HEp-2 cells) and antibodies to extractable nuclear antigens (anti-ENA) (by immunodiffusion - ID - and counterimmunoelectrophoresis - CIE). In localized disease, antinuclear autoimmunity was limited to 1 FANA positive serum (14%); in systemic disease, the prevalence of FANA was 94% and that of anti-FANA ranged from 29% to 49% (by ID and CIE, respectively). The commonest ENA system, Scl-70, could be easily detected by CIE, in spite of the reported basic nature of the antigen. The anticentromere antibody occurred only in patients with acrosclerosis (7/26 - 27%), whereas the association of nucleolar + homogeneous FANA, as well as the anti-Scl-70, were found more frequently in diffuse scleroderma (9/9 - 100% and 6/9 - 67%, respectively). The presence of the anticentromere antibody excluded that of any anti-ENA, while a close association was found between nucleolar + homogeneous FANA and the anti-Scl-70. Pulmonary involvement was significantly more frequent in nucleolar + homogeneous FANA positive patients; moreover, in two cases the same pattern proved to predict the development of diffuse scleroderma.

AB - Sera from 7 patients with localized and 35 with systemic scleroderma were studied for the presence of fluorescent antinuclear antibodies (FANA) (by indirect immunofluorescence on HEp-2 cells) and antibodies to extractable nuclear antigens (anti-ENA) (by immunodiffusion - ID - and counterimmunoelectrophoresis - CIE). In localized disease, antinuclear autoimmunity was limited to 1 FANA positive serum (14%); in systemic disease, the prevalence of FANA was 94% and that of anti-FANA ranged from 29% to 49% (by ID and CIE, respectively). The commonest ENA system, Scl-70, could be easily detected by CIE, in spite of the reported basic nature of the antigen. The anticentromere antibody occurred only in patients with acrosclerosis (7/26 - 27%), whereas the association of nucleolar + homogeneous FANA, as well as the anti-Scl-70, were found more frequently in diffuse scleroderma (9/9 - 100% and 6/9 - 67%, respectively). The presence of the anticentromere antibody excluded that of any anti-ENA, while a close association was found between nucleolar + homogeneous FANA and the anti-Scl-70. Pulmonary involvement was significantly more frequent in nucleolar + homogeneous FANA positive patients; moreover, in two cases the same pattern proved to predict the development of diffuse scleroderma.

UR - http://www.scopus.com/inward/record.url?scp=0023195117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023195117&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 23

EP - 28

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 1

ER -